Apellis Pharmaceuticals, Inc.
APLSDrugs in Pipeline
8
Phase 3 Programs
6
Upcoming Catalysts
3
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
How APLS's past catalysts played out
APL2
FSGS
APL-2
Paroxysmal Nocturnal Hemoglobinuria
PEGCETACOPLAN (APL-2)
Geographic Atrophy Secondary to Age-related Macular Degeneration
APL-2, Pegcetacoplan
Geographic Atrophy Secondary to Age-related Macular Degeneration
Pegcetacoplan
C3G
Soliris
Paroxysmal Nocturnal Hemoglobinuria
APL-9
COVID
APL-3007, pegcetacoplan (APL-2)
Geographic Atrophy Secondary to Age-related Macular Degeneration
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
APL2 | Phase 3 | FSGS | - | - |
APL-2 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
PEGCETACOPLAN (APL-2) | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
APL-2, Pegcetacoplan | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
Pegcetacoplan | Phase 3 | C3G | - | - |
Soliris | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
APL-9 | Phase 2 | COVID | - | - |
APL-3007, pegcetacoplan (APL-2) | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
Paroxysmal Nocturnal Hemoglobinuria
2 drugs in this indication
Geographic Atrophy Secondary to Age-related Macular Degeneration
2 drugs in this indication
FSGS
1 drug in this indication
COVID
1 drug in this indication
C3G
1 drug in this indication
Complement 3 Glomerulopathy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Apellis Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Apellis Pharmaceuticals, Inc.'s (APLS) pipeline across Phase 3, Phase 2. Its lead program is APL2 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Apellis Pharmaceuticals, Inc.'s next FDA catalyst?→
Apellis Pharmaceuticals, Inc.'s (APLS) next tracked catalyst is a Phase 2 expected June 25, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track APLS biotech catalysts?→
Add APLS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Apellis Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.